BJMO - volume 12, issue 3, february 2018
B. Sautois MD, PhD, J.C. Goeminne MD, S. Rottey MD, PhD, D. Schrijvers MD, PhD, F. Van Aelst MD, S. Van Bruwaene MD, PhD, S. Watkins , A. Simmons , Jowell Go , Melanie Collins , T. Golsorkhi , W. Abida MD, PhD, C. Ryan , Howard Scher , S. Chowdhury
BJMO - volume 12, issue 9, february 2018
S. De Keukeleire MSc, V. Kruse MD, PhD, S. Rottey MD, PhD
Immune checkpoint inhibition (ICI) has been acknowledged as a breakthrough treatment in multiple advanced cancer types. This is also the case in metastatic Merkel Cell Carcinoma (MCC), a disease that is historically associated with a poor prognosis. Recently, several randomized trials demonstrated superior results of ICI compared to chemotherapeutic agents in patients with metastatic MCC, with less toxicity, an increased overall survival (OS), and more durable responses. Therefore, ICI is now generally considered as a new standard treatment option in this setting.
Read moreBJMO - volume 11, issue 7, november 2017
T. Vermassen PhD, S. Rottey MD, PhD
From the 8th till the 12th of September, Madrid was the host city for the 2017 ESMO Congress. The central theme of the congress was ‘Integrating science into oncology for a better patient outcome’, as it is crucial that researchers and clinicians exchange knowledge in an era of deep understanding of the molecular biology underlying the development of cancer. ESMO 2017 was attended by almost 24,000 registered attendees. This report will highlight eleven key studies concerning genitourinary cancers presented during the meeting.
(BELG J ONCOL 2017;11(7):326–333)
Read moreBJMO - volume 11, issue 4, september 2017
T. Vermassen PhD, S. Rottey MD, PhD
From June 2nd till June 6th, Chicago was host for the 53rd ASCO annual meeting. The theme for this year’s venue was ‘Making a Difference in Cancer Care WITH YOU’. With over 35,000 registered attendees from over 100 countries worldwide and almost 6,000 submitted abstracts, this year’s meeting was a great success. This report will highlight 7 key studies concerning genitourinary cancers presented during the meeting.
Read moreBJMO - 2017, issue 3, february 2017
A. De Meulenaere MD, T. Vermassen PhD, L. Ferdinande MD, PhD, S. Rottey MD, PhD
BJMO - volume 10, issue 8, december 2016
T. Vermassen PhD, S. Rottey MD, PhD
The central theme of ESMO 2016 was ‘From disease treatment to patient care’, and the congress aimed at further integrating clinical research with patient needs. This report will highlight 9 key studies concerning renal cell carcinoma and metastatic prostate cancer, some of which were presented during one of the presidential sessions of the meeting.
(BELG J MED ONCOL 2016;10(8):295–300)
Read moreBJMO - volume 10, issue 7, november 2016
T. Vermassen PhD, A. De Meulenaere MD, M. Van de Walle MD, S. Rottey MD, PhD
Renal cell carcinoma accounts for 2.4% of all malignancies worldwide diagnosed with 338,000 estimated new cases globally in 2012. In the last decade, the therapeutic landscape for renal cell carcinoma patients has changed tremendously. In this review, we will summarise the treatment options currently available for clear-cell localised, advanced and metastatic renal cell carcinoma; as stated in the ESMO clinical practice guidelines, the EAU guidelines and the NCCN guidelines. Furthermore we will discuss the recommended therapies in patients diagnosed with non-clear cell tumours.
(BELG J MED ONCOL 2016;10(7):256–262)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
